glp-1 cardiovascular outcomes trial results august 2025 Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials - Yin - ISPOR 2025: Exploring reasons for

Iron deficiency develops in a meaningful percentage of patients on GLP-1 receptor agonists like semaglutide, often appearing 3-6 months into treatment

This article is for educational purposes only and is not medical advice

Everyone deserves care that is holistic, respectful, and tailored to their full lived experience

Conversely, patients with prediabetes or early type 2 diabetes may achieve adequate glycemic control through intensive dietary modification, potentially delaying or avoiding medication initiation

Metabolism 2010;59:123-133

This recommendation has come under scrutiny and is challenged based upon multiple factors, including physical activity, metabolic needs, and age